|
The customer reported false negative fy(a) antigen typing results when using seraclone anti-fy(a).The customer used various fy(a+b+) positive reagent red blood cells from two different manufacturers.The customer did neither return the supposedly defective product for investigational testing nor the red blood cells that had caused the false negative test result.Therefore our quality control laboratory tested their retention sample with different donor and reagent red blood cells for potency and specificity.For the specificity testing our quality control laboratory used screening and panel cells of a competitor as well as the reagent red blood cells of the biotest cell product line.All positive and negative reactions were correct.We did not observe any false negative reaction.The required minimum titer of 16 was exceeded.Testing by our quality control laboratory confirmed that the allegedly defective lot of seraclone anti-fy(a) functions correctly.A review of the batch record documentation showed no irregularities which might have negatively affected the quality of the allegedly defective lot.
|